UNITED STATES SECURITIES AND EXCHANGE COMMISSION
|
Washington, DC 20549
|
______________________
|
FORM 8-K
|
CURRENT REPORT PURSUANT
|
TO SECTION 13 OR 15(D) OF THE
|
SECURITIES EXCHANGE ACT OF 1934
|
November 22, 2011
|
Date of Report (Date of earliest event reported)
|
BOVIE MEDICAL CORPORATION
|
(Exact name of registrant as specified in its Charter)
|
Delaware
|
012183
|
11-2644611
|
||
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
734 Walt Whitman Road, Melville, New York 11747
|
(Address of principal executive offices) (Zip Code)
|
(631) 421-5452
|
Registrant's telephone number, including area code
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
·
|
Mr. Citronowicz will immediately forfeit all stock options issued to him (whether vested or unvested), totaling 75,000 stock options;
|
·
|
Mr. Citronowicz’s employment agreement with the Company will be immediately cancelled and he will continue to be employed by the Company on an at-will basis;
|
·
|
Mr. Citronowicz will be immediately reassigned to the position of Director of Strategic Development, reporting to J. Robert Saron, the Company’s President and Chief Sales and Marketing Officer; and
|
·
|
Mr. Citronowicz’s base annual salary will be reduced from approximately $220,000 to approximately $196,000.
|
Date: November 29, 2011
|
BOVIE MEDICAL CORPORATION
|
||
By: /s/ Andrew Makrides
|
|||
Andrew Makrides
|
|||
Chief Executive Officer and
Chairman of the Board
|